


1 Supplemental Figures and Figure Legends




2

3 **Figure S1. IFN γ enhanced glycolysis of HUVECs.** (A) Glycolysis of HUVECs
4 (3000 cells per well) stimulated with IFN γ (30 ng/mL) . (B) Statistical analysis of
5 glycolytic function of HUVECs with IFN γ stimulation. Statistical analyses using
6 Nonparametric Mann-Whitney test. Values are mean \pm SEM. *, $p < 0.05$;

7

8



9

10 **Figure S2. Heatmap of transcript levels of genes in glycolysis.** The expressions of


11 glycolysis-related genes of isolated tumour vascular endothelial cells from mouse

12 tumour tissues with indicated treatments. Statistical analyses using Z-score

13 normalization. N=3 for each group. Color scale: red, high expression; blue, low

14 expression.

15



16

17 **Figure S3. Inhibition of ERK and P38 do not affect IFN γ -stimulated glycolysis of**

18 **endothelial cells.** (A) Glycolysis of endothelial cells stimulated with IFN γ or IFN γ

19 plus ERK inhibitor (U0126, 10 μ M). (B) Statistical analysis of glycolysis of

20 endothelial cells with treatment described as (A). Statistical analyses using

21 Nonparametric Mann-Whitney test. Values are mean \pm SEM. **, $p < 0.01$; (C)

22 Glycolysis of endothelial cells stimulated with IFN γ or IFN γ plus P38 inhibitor

23 (SB202190, 10 μ M). (D) Statistical analysis of glycolysis of endothelial cells with


24 treatment described as (C). Statistical analyses using Nonparametric Mann-Whitney

25 test. Values are mean \pm SEM. *, $p < 0.05$.

26

27

28



29

30 **Figure S4. Neutralizing IFN γ reversed cisplatin-reduced pericyte coverage.**


31 Representative images and quantifications of pericyte coverage in tumour tissues with

32 different treatments. Scale bar, 100 μ m. Nonparametric Mann-Whitney test. Values

33 are mean \pm SEM. *, $p < 0.05$.

34

35



36


37 **Figure S5. Tumour blood vessels are enwrapped by fibronectin in LLC tumour**

38 **with cisplatin treatment.** Co-staining of CD31 and fibronectin in tumour sections

39 from control (Con) or cisplatin (Cpt) treated LLC tumours. Scale bar, 100 μ m.

40

41



42

43 **Figure S6. Characterization and release profiles of the CREKA-lipo-anti-IFN γ**

44 **nanoparticle. (A-C)** Size distribution and zeta potential characterization of


45 CREKA-lipo and CREKA-lipo-anti-IFN γ at (Day 0) (n=3) in the PBS buffer at room

46 temperature. The data of zeta potential are presented as the mean \pm standard deviation

47 (n=3). **(D)** The drug release profiles of CREKA-Lipo-anti-IFN γ at two pH conditions.

48 The data are presented as the mean \pm standard deviation (n=3).

49



50

51 **Figure S7. Evaluation of the biosafety of CREKA-lipo-anti-IFN γ *in vivo*.** (A) The
 52 effects of CREKA-lipo-anti-IFN γ on the serum level of aspartate aminotransferase
 53 (AST), alanine aminotransferase (ALT) related to liver function, and creatinine (CR)
 54 related to kidney function. Statistical analyses using nonparametric Mann-Whitney
 55 test (n = 5-6 for each group). (B) CREKA-lipo-anti-IFN γ treatment showed no visible
 56 damage to the major organs of mice as indicated by H&E staining (n = 3 for each
 57 group). Scale bar, 200 μ m.

58